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ABSTRACT 
Aims: The landmark STICH trial found that surgical revascularization compared to medical 
therapy alone improved survival in patients with heart failure (HF) of ischemic etiology and an 
ejection fraction (EF) <35%. However, the interaction between the burden of medical 
comorbidities and the benefit from surgical revascularization has not been previously described 
in patients with ischemic cardiomyopathy. 
Methods: The STICH trial (ClinicalTrials.gov Number: NCT00023595) enrolled patients >18 
years of age with coronary artery disease amenable to coronary artery bypass grafting (CABG) 
and an EF <35%. Eligible participants were randomly assigned 1:1 to receive medical therapy 
(MED) (602 patients) or MED/CABG (610 patient). A modified Charlson Comorbidity Index 
(CCI) based on the availability of data and study definitions was calculated by summing the 
weighted points for all comorbid conditions. Patients were divided into mild/moderate (CCI 1-4) 
and severe (CCI >5) comorbidity. Cox proportional hazards models were used to evaluate the 
association between CCI and outcomes. The interaction between severity of comorbidity and 
treatment effect was assessed with the log-rank test.  
Results: The study population included 349 patients (29%) with a mild/moderate CCI score and 
863 patients (71%) with a severe CCI score. Patients with a severe CCI score had greater 
functional limitations based on 6-minute walk test and impairments in health-related quality of 
life as assessed by the Kansas City Cardiomyopathy Questionnaire. A total of 161 patients 
(Kaplan-Meier [KM] rate = 50%) with a mild/moderate CCI score and 579 patients (KM rate = 
69%) with a severe CCI score died over a median follow-up of 9.8 years. After adjusting for 
baseline confounders, patients with a severe CCI score were at higher risk for all-cause mortality 
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(Hazard Ratio [HR] 1.44, 95% confidence interval [CI] 1.19-1.74; p-value <0.001). There was 
no interaction between CCI score and treatment effect on survival (p-value = 0.756). 
Conclusions: More than 70% of patients had a severe burden of medical comorbidities at 
baseline which was independently associated with increased risk of death. There was not a 
differential benefit of surgical revascularization with respect to survival based on severity of 
comorbidity.  
Key Words: heart failure, ischemic cardiomyopathy, reduced ejection fraction, coronary artery 
bypass grafting, multimorbidity, survival 
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INTRODUCTION 
Heart failure (HF) is a public health problem of pandemic proportions with an estimated 
38 million patients worldwide (1-3). Cardiac and non-cardiac comorbidities are highly prevalent 
in HF and many coexisting medical conditions have been independently associated with 
increased risk of morbidity and mortality (4, 5). The Charlson Comorbidity Index (CCI) is a 
convenient bedside tool that allows physicians to assess a patient’s burden of common cardiac 
and non-cardiac conditions and estimate the corresponding 10-year survival (6, 7).  
The Surgical Treatment for Ischemic Heart Failure (STICH) trial(8-11) provides a 
unique opportunity to systematically describe the burden of cardiac and non-cardiac conditions 
(i.e. defined by CCI) as well as the impact of severity of comorbid illness on the relative efficacy 
and safety of medical therapy alone (i.e. MED) vs. medical therapy plus coronary artery bypass 
grafting (i.e. MED/CABG) in patients with ischemic cardiomyopathy and severe left ventricular 
(LV) dysfunction. Specifically, the objectives of this work are to 1.) describe the level of 
comorbidity using the CCI, 2.) study the association between the burden of comorbid conditions 
and survival, and 3.) evaluate the efficacy of MED vs. MED/CABG based on severity of 
comorbidity in HF patients of ischemic etiology with an ejection fraction (EF) <35%. 
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METHODS 
Overview 
 The study design (8) and primary results (9-11) of the STICH trial (ClinicalTrials.gov 
Number: NCT00023595) have been previously reported. Briefly, STICH was an international, 
multicenter, randomized, active-controlled trial designed to assess the relative efficacy of three 
possible therapeutic options: medical therapy alone (i.e. MED), medical therapy plus CABG (i.e. 
MED/CABG), or medical therapy plus CABG and surgical ventricular reconstruction. The 
present analysis includes the 1212 patients enrolled in the hypothesis 1 component of the trial 
(i.e. MED vs. MED/CABG) at 99 centers in 22 countries between July 24, 2002 and May 5, 
2007. Patients >18 years of age with coronary artery disease (CAD) that was amenable to CABG 
and an EF <35% within 3 months of trial entry were eligible for enrollment. Patients with a 
>50% left main coronary artery stenosis, Canadian Cardiovascular Society (CCS) grade III or IV 
angina (i.e. markedly limiting ordinary activity), a non-cardiac illness imposing substantial 
operative mortality or with a limited life-expectancy of <3 years, or conditions/circumstances 
limiting treatment adherence were excluded from participation.  
 Eligible participants were randomly assigned 1:1 to receive MED (602 patients) or 
MED/CABG (610 patient). A local cardiologist was responsible for managing background 
guideline-directed medical therapy for CAD and HF. Adherence to guideline recommendations 
was emphasized and monitored by a medical therapy committee. Cardiac surgery was performed 
by surgeons who were required to provide data on a minimum of 25 patients with an EF <40% in 
whom they had performed CABG with an operative mortality <5%. CABG was performed 
within 14 days of enrollment. All patients were asked to return for follow-up visits at the time of 
discharge or at 30 days, every 4 months for the first year, and every 6 months thereafter.  
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Charlson Comorbidity Index 
 The development and validation of the CCI has been previously described (6, 7). Briefly, 
the CCI accounts for 16 medical comorbidities and assigns each condition 1, 2, 3, or 6 points 
depending on the associated mortality risk. A modified CCI score (i.e. based on the availability 
of data and study definitions) was computed for each patient enrolled in the STICH trial by 
summing the weighted points for all comorbid conditions (Supplemental Table 1). A combined 
age-comorbidity score was subsequently calculated by adding 1 point for each decade of life 
over 40 years of age to account for the risk of comorbid death attributable to age. For example, a 
60-year old patient with HF and a prior myocardial infarction would have a combined age-
comorbidity score (i.e. hereafter referred to simply as the CCI) of 4 (i.e. HF = 1 point, 
myocardial infraction = 1 point, and age of 60 years = 2 points). 
 The predicted 10-year mortality based on the CCI was calculated (ref) as follows: 
X = e0.9(CCI)  
Mortality = 1-0.983X 
Outcomes 
The primary endpoint was all-cause mortality. Secondary endpoints included 
cardiovascular (CV) mortality and the composite of all-cause mortality and CV hospitalizations. 
Blinding was not pursued due to the nature of the surgical intervention, mode of death and CV 
hospitalizations for each patient were adjudicated by an independent clinical events committee 
who were unaware of treatment assignment.  
Statistical Analysis 
All categorical data were reported as a count (percentage) and continuous data as a mean 
(standard deviation [SD]) and/or median (25th, 75th percentiles). Patients were divided into 
mild/moderate (i.e. defined as CCI 1-4) and severe (i.e. defined as CCI >5) comorbid illness. 
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Baseline clinical characteristics including demographics, medical history, medication use, 
laboratory values, quality of life, and exercise testing were compared between groups. 
Comparisons for continuous variables were based on the Wilcoxon rank-sum test, while 
categorical variables were assessed using Pearson’s chi-square test or Fisher’s exact test as 
appropriate. Ten-year mortality is calculated in the CCI severity groups using the Kaplan-Meier 
method. The Kaplan-Meier estimates for each CCI score were plotted with 95% CIs in a figure, 
that included the predicted probability of mortality using the previously published CCI equation 
(6, 7). 
Cox proportional hazards regression models were used to evaluate the association 
between CCI as a categorical variable (i.e. mild/moderate = CCI 1-4 vs. severe = CCI >5) as well 
as continuous variable (i.e. calculated as the risk per additional CCI point) and outcomes. 
Multivariable Cox models were adjusted for following baseline covariates: sex, race, region, 
blood pressure, heart rate, Canadian Cardiovascular Society (CCS) angina class, New York 
Heart Association (NYHA) class, atrial fibrillation/flutter, hyperlipidemia, hypertension, prior 
CABG, prior percutaneous coronary intervention (PCI), number of diseased vessels, left main 
stenosis, proximal left anterior descending (LAD) stenosis, left ventricular EF (LVEF), left 
ventricular end-systolic volume index (LVESVI), moderate or severe mitral regurgitation, 
hemoglobin, sodium and estimated glomerular filtration rate (eGFR) as previously identified as 
being associated with clinical outcomes (12). The predicted probabilities (95% CI) for 10-year 
mortality were estimated from an unadjusted Cox model, that included CCI (as a continuous 
covariate). The interaction between severity of comorbidity as a categorical (i.e. mild/moderate = 
CCI 1-4, vs. severe = CCI >5) and continuous variable and randomized treatment (i.e. 
CABG/MED vs. MED) with respect to all-cause mortality was assessed with adjusted Cox 
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models that included the CCI severity-by-treatment interaction. Relationships are displayed with 
Kaplan-Meier plots stratified by treatment separately in the mild/moderate and severe 
comorbidity groups along with unadjusted hazard ratios (95% CI) and interaction p-value, KM 
10-year rates, number of events, and forest plot and spline curves stratified by treatment showing 
comorbidity level as a continuous variable with 95% CI and interaction p-value. 
P-values <0.05 from two-sided tests were considered statistically significant. 
Adjustments were not made for multiple comparisons. All analyses were performed using SAS 
9.4 (SAS Institute Inc. Cary, North Carolina, USA). 
Funding and Manuscript Preparation 
This work was supported by grants U01HL69015, U01HL69013, and RO1HL105853 
from the National Institutes of Health/National Heart, Lung, and Blood Institute (Bethesda, MD). 
Database management and statistical analyses were performed by the Duke Clinical Research 
Institute (Durham, NC). This work is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of Health or National Heart, 
Lung, and Blood Institute. 
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RESULTS 
Study Population  
 A total of 1212 patients with CAD that was amenable to CABG and an EF <35% were 
included in the present analysis (Table 1). Study participants were a median of 60 (54, 67) years 
old and 88% were male. The median EF for the study population was 28% (22%, 34%). The 
median CCI score was 5 (4, 7) with a minimum of 1 and a maximum of 12. A total of 349 
patients (29%) had a mild/moderate CCI score and 863 patients (71%) had a severe CCI score at 
baseline. At the time of randomization, 95% of patients reported no angina or CCS I/II angina 
and approximately 85% of patients reported New York Heart Association (NYHA) functional 
class II/III symptoms. Patients were well-treated with guideline-directed medical therapy for 
CAD and HF at baseline. 
Patient Characteristics by Comorbidity Level 
Patients with severe CCI score were more likely to self-identify as white and had greater 
functional limitations based on 6-minute walk test (6-MWT) and impairments in health-related 
quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 
baseline (Table 1). In contrast, there were no statistically significant differences between patients 
with mild/moderate vs. severe CCI scores in the rate of prior revascularization (i.e. percutaneous 
coronary intervention [PCI] or coronary artery bypass grafting [CABG]), LVEF and LV end-
systolic volume index (LVESVI) measurements, coronary anatomy, CCS angina or NYHA 
functional class, or guideline-directed medical therapy for CAD or HF.   
Comorbidity Severity and Clinical Outcomes 
 The 10-year mortality in the STICH population ranged from approximately 25% for 
patients with a CCI score of 1 and approached 100% for patients with a CCI score of 12 (Figure 
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1A). A total of 161 patients (50%) with a mild/moderate CCI score and 579 patients (69%) with 
a severe CCI score died over a median follow-up of 9.8 years (Table 2). In addition, the 
composite of all-cause mortality or CV hospitalization was reached in 254 patients (79%) with a 
mild/moderate CCI score and 731 patients (87%) with a severe CCI score over the same 
timeframe. The predicted 10-year mortality based on the CCI and the actual mortality for the 
STICH cohort are shown in Figure 1B. In general, the estimated 10-year mortality derived from 
the CCI tended to underestimate the risk of death for patients with a CCI score below 4 and 
overestimate the risk of death for patients with a CCI score above 4. 
Patients with a severe CCI score were at higher risk for all-cause mortality (Hazard Ratio 
[HR] 1.44, 95% confidence interval [CI] 1.19-1.74; p-value <0.001), CV mortality (HR 1.35, 
95% CI 1.09-1.68; p-value = 0.006), and all-cause mortality or CV hospitalization (HR 1.22, 
95% CI 1.04-1.43; p-value = 0.012). The incremental risk of an adverse event per 1-point 
increase in CCI score was comparable for all-cause mortality (HR 1.12, 95% CI 1.06-1.18; p-
value <0.001), CV mortality (HR 1.11, 95% CI 1.04-1.18; p-value <0.001), and all-cause 
mortality or CV hospitalization (HR 1.07, 95% CI 1.02-1.12; p-value = 0.003).  
Efficacy of Surgical Revascularization by Comorbidity Level 
 There was no interaction between CCI score (i.e. mild/moderate vs. severe) and treatment 
effect (i.e. MED vs. MED/CABG) with respect to all-cause (Figure 2A) or CV mortality 
(Figure 2B) at 10 years in the intention-to-treat population. In contrast, although patients 
randomized to MED/CABG were less likely to reach the composite of all-cause mortality or CV 
hospitalization irrespective of CCI score, patients with a mild/moderate CCI score derived a 
more robust benefit from surgical revascularization over the same timeframe (Figure 2C). A 
sensitivity analysis did not reveal an interaction between CCI score and treatment effect with 
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respect to all-cause mortality, CV mortality, or the composite of all-cause mortality or CV 
hospitalization in the as-treated cohort (Supplemental Figure 1). 
 Figure 3 shows spline curves for all-cause mortality, CV mortality, and the composite of 
all-cause mortality or CV hospitalization at 1, 5, and 10 years for the intention-to-treat 
population. In general, the results of the interaction analyses with CCI score as a continuous 
variable were consistent with those observed with CCI score as a categorical variable (i.e. 
mild/moderate vs. severe). For example, there was no interaction between CCI score as a 
continuous variable and treatment effect (i.e. MED vs. MED/CABG) with respect to all-cause (p-
value = 0.115) or CV mortality (p-value = 0.275). Similarly, patients with a CCI score in the 
mild/moderate range (i.e. 1-4) undergoing surgical revascularization experienced an earlier and 
more marked improvement in the composite of all-cause mortality or CV hospitalization 
compared to patients receiving medical therapy alone (p-value = 0.021).
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DISCUSSION 
 This study found that more than 70% of the patients enrolled in the STICH trial had a 
severe burden of medical comorbidities at baseline. Patients with a severe level of comorbidity 
had greater functional limitations and impairments in health-related quality of life. In addition, 
these patients experienced an exceptionally poor prognosis with mortality approaching 70% at 10 
years. After adjusting for potential confounders, all-cause mortality was almost 45% higher for 
patients with a severe CCI score and the incremental risk of death per 1-point increase in CCI 
score was in excess of 10%. However, patients with ischemic cardiomyopathy and a severe 
burden of medical comorbidities derived a comparable survival benefit from surgical 
revascularization over the duration of follow-up. 
 It is notable that more than 70% of study participants had a CCI score in the severe range. 
However, this finding likely underestimates the real-world burden of medical comorbidities in 
patients with ischemic cardiomyopathy and severe LV systolic dysfunction as the STICH 
protocol excluded participants with a non-cardiac illness imposing substantial operative mortality 
or with a limited life-expectancy (8). There is a growing appreciation of the clinical impact of 
multimorbidity on the patient journey in HF (4). This assertion is supported by the fact that 
patients with a severe CCI score had worse functional capacity (i.e. 6-MWT) and health-related 
quality of life (i.e. KCCQ). These differences were not only statistically significant but also 
consistent with the generally accepted minimal clinically important difference for these 
assessments (13, 14). Interestingly, despite differences in age and comorbidity profile between 
patients with mild/moderate and severe CCI scores, there was very little difference in underlying 
cardiac substrate including coronary anatomy, echocardiographic parameters of remodeling, and 
symptom status (i.e. CCS angina and/or NYHA functional class). In addition, patients with a 
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severe CCI score were equally likely to be treated with evidence-based medications for CAD and 
HF despite the fact that certain non-cardiac comorbidities may lead to real or perceived barriers 
to optimal implementation of guideline-directed medical therapies (15, 16).   
 The CCI was initially developed as a method for quantifying the degree of comorbidity 
and assessing prognosis in longitudinal cohort studies (6, 7). Although a reliable and accurate 
research tool, there is a more limited experience with the CCI in a HF population and its clinical 
utility is not well-established. Of note, this study found a relatively linear relationship between 
CCI score and all-cause mortality at 10 years with the incremental risk of death an estimated 
12% per 1-point increase in CCI score independent of traditional prognostic indicators. In 
addition, since the CCI incorporates age and cardiac and non-cardiac comorbidities, the risk of 
CV and non-CV mortality tended to rise proportionally with increasing CCI score and it was 
found to be equally useful when estimating all-cause and CV-specific mortality in this patient 
population. Thus, the CCI may supplement clinical judgment and play a meaningful role when 
discussing life-expectancy and prognosis with HF patients. However, it should be noted that the 
CCI was originally developed in a relatively low-risk cohort. As a result, the previously 
published regression equation did not perform well in the high-risk STICH population and tended 
to underestimate the risk of death in patients with a low/moderate CCI score and overestimate 
the risk of death in patients with a severe CCI score. This finding suggests that additional 
research is required to prospectively validate the prognostic potential of the CCI in patients with 
HF in order to provide reliable and accurate estimates of survival based on comorbidity burden. 
 More importantly, in an era of personalized medicine it is relevant to consider the impact 
of severity of comorbidity on the relative efficacy and safety of surgical revascularization in 
patients with ischemic cardiomyopathy and severe LV systolic dysfunction. In general, patients 
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undergoing major cardiovascular surgery are exposed to perioperative/post-operative 
complications with the expectation that by correcting the underlying cardiac pathology this 
upfront risk will eventually be offset by a long-term reduction in CV morbidity and mortality. 
This generalization is consistent with the primary results of the STICH trial which demonstrated 
that although mortality was initially higher in patients randomized to surgical revascularization, 
the survival curves crossed over after the 2-year mark and a statistically significant benefit 
emerged over a median follow-up of 9.8 years (9-11). In contrast, this study found that among 
patients with a mild/moderate CCI, the Kaplan-Meier plots for all-cause mortality for MED vs. 
MED/CABG did not exhibit this crossover phenomenon but rather paralleled one another 
initially before demonstrating a potentially earlier and more pronounced survival benefit with 
surgical revascularization. In addition, although patients randomized to MED/CABG were at 
lower risk for the composite of all-cause mortality or CV hospitalization irrespective of CCI 
score, patients with a mild/moderate CCI score derived a more robust benefit from surgical 
revascularization driven by a reduction in CV hospitalizations. Thus, among patients with HF of 
ischemic etiology who are young and relatively free of comorbid conditions, surgical 
revascularization poses minimal upfront risk and these patients experience an early and dramatic 
improvement in all-cause and CV-specific morbidity and mortality compared to medical therapy 
alone. However, it cannot be overemphasized that this study found no interaction between 
comorbidity level and all-cause and CV mortality at 10 years suggesting that elderly patients 
with a severe burden of medical comorbidities should not be denied surgical revascularization 
based on these factors alone. The decision to refer a patient with ischemic cardiomyopathy and 
severe LV systolic dysfunction for CABG should be individualized and take into account age 
(17), comorbidity profile, coronary anatomy (i.e. single- vs. triple-vessel CAD) (18), 
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echocardiographic parameters of remodeling (i.e. LVEF and LVESVI) (19), and functional 
capacity (20).  
There are several limitations of the data that should be acknowledged. First, patients with 
a non-cardiac illness imposing substantial operative mortality or with a limited life-expectancy 
were excluded from enrollment potentially restricting the generalizability of the data to an 
otherwise unselected real-world population of patients with ischemic cardiomyopathy and severe 
LV systolic dysfunction. Second, the STICH protocol did not require reporting of several 
medical comorbidities (i.e. liver disease and acute immunodeficiency syndrome) included in the 
CCI. Third, although more than 70% of patients had a severe level of comorbidity there were 
very few patients with a CCI >8 (i.e. ~6%) and the possibility that there was heterogeneity in 
treatment effect (i.e. MED vs. MED/CABG) cannot be excluded for this subset of the population. 
Fourth, early crossover occurred in approximately 20% of patients enrolled in the STICH trial 
and a differential crossover rate between patients with a mild/moderate vs. severe CCI may have 
biased the results towards the null hypothesis and impended the ability to detect an interaction 
between comorbidity severity and treatment effect (21). However, a sensitivity analysis was 
performed and found no interaction between CCI severity and treatment effect in the as-treated 
cohort. Finally, due to the nature of surgical revascularization, physicians and patients were 
necessarily unblinded to treatment assignment although outcomes were adjudicated by a blinded 
and independent clinical events committee. 
In conclusion, more than 70% of patients with ischemic cardiomyopathy and severe LV 
systolic dysfunction had a severe burden of medical comorbidities. Multimorbidity was 
associated with greater functional limitations and impairments in health-related quality of life 
and decreased survival. There was not a differential response to MED vs. MED/CABG with 
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respect to all-cause and CV-specific mortality based on severity of comorbidity among patients 
with ischemic cardiomyopathy and severe LV systolic dysfunction. Additional research is 
required to identify patient and procedural factors that may define patient groups who may derive 
a more robust or more limited response to surgical revascularization compared to medical 
therapy alone. 
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Table 1. Baseline patient characteristics by level of comorbidity. All values reported as N (%) 
and median (25th, 75thpercentiles). 
 
All Patients  
(N=1212) 
Mild/Moderate 
(N=349) 
Severe  
(N=863) p-value 
Demographics     
Age (years) 60 (54, 67) 53 (48, 57) 63 (57, 70) <0.001 
Female sex 148 (12%) 35 (10%) 113 (13%) 0.140 
Race    <0.001 
White 827 (68%) 206 (59%) 621 (72%)  
Black 31 (3%) 4 (1%) 27 (3%)  
Asian 209 (17%) 88 (25%) 121 (14%)  
Other 145 (12%) 51 (15%) 94 (11%)  
Vitals/Physical Examination     
BMI (kg/m2) 27 (24, 30) 26 (24, 29) 27 (24, 30) 0.057 
HR (bpm) 74 (66, 82) 74 (68, 82) 73 (65, 80) 0.050 
SBP (mmHg) 120 (110, 130) 120 (110, 130) 120 (110, 130) 0.002 
CCS angina class    0.115 
0 442 (37%) 112 (32%) 330 (38%)  
I 187 (15%) 53 (15%) 134 (16%)  
II 525 (43%) 171 (49%) 354 (41%)  
III 48 (4%) 11 (3%) 37 (4%)  
IV 10 (1%) 2 (1%) 8 (1%)  
NYHA class    0.069 
I 139 (12%) 44 (13%) 95 (11%)  
II 626 (52%) 195 (56%) 431 (50%)  
III 412 (34%) 104 (30%) 308 (36%)  
IV 35 (3%) 6 (2%) 29 (3%)  
Laboratory Values     
Hg (g/dL) 13.9 (12.7, 14.9) 14.3 (13.3, 15.2) 13.7 (12.5, 14.8) <0.001 
sCr (mg/dL) 1.1 (0.9, 1.3) 1.0 (0.9, 1.2) 1.1 (1.0, 1.3) <0.001 
eGFR (mL/min/1.73 m2) 77 (61, 96) 90 (74, 107) 71 (57, 89) <0.001 
Sodium (mEq/L) 140 (137, 142) 139 (137, 142) 140 (137, 142) 0.381 
BUN (mg/dL) 23 (16, 37) 21 (16, 32) 23 (17, 38) 0.049 
Baseline Assessments     
LVEF 28 (22, 34) 28 (23, 34) 27 (22, 34) 0.443 
ESVI (mL/m2) 78 (61, 99) 78 (61, 99) 78 (61, 99) 0.873 
6-MWT (m) 320 (200, 400) 340 (240, 410) 310 (180, 390) <0.001 
KCCQ  62 (44, 79) 64 (50, 81) 60 (43, 78) 0.007 
Medical Comorbidities     
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All Patients  
(N=1212) 
Mild/Moderate 
(N=349) 
Severe  
(N=863) p-value 
Prior PCI 156 (13%) 35 (10%) 121 (14%) 0.060 
Prior CABG 36 (3%) 10 (3%) 26 (3%) 0.891 
Moderate or severe MR 220 (18.2%) 60 (17.2%) 160 (18.6%) 0.584 
PVD 184 (15%) 6 (2%) 178 (21%) <0.001 
MI 934 (77%) 225 (65%) 709 (82%) <0.001 
CVA 92 (8%) 2 (1%) 90 (10%) <0.001 
HL 730 (60%) 188 (54%) 542 (63%) 0.004 
HTN 728 (60%) 183 (52%) 545 (63%) <0.001 
DM 478 (39%) 46 (13%) 432 (50%) <0.001 
Afib/aflutter 153 (13%) 30 (9%) 123 (14%) 0.007 
CKD 94 (8%) 3 (1%) 91 (11%) <0.001 
Cancer 14 (1%) 0 (0%) 14 (2%) 0.014 
Depression 76 (6%) 4 (1%) 72 (8%) <0.001 
Current Smoking 252 (21%) 39 (11%) 213 (25%) <0.001 
Baseline Medications     
ACEI 996 (82%) 290 (83%) 706 (82%) 0.596 
ARB 115 (10%) 23 (7%) 92 (11%) 0.029 
β-Blocker 1036 (86%) 298 (85%) 738 (86%) 0.954 
MRA 556 (46%) 173 (50%) 383 (44%) 0.101 
Loop Diuretic 791 (65%) 214 (61%) 577 (67%) 0.063 
Digoxin 245 (20%) 75 (22%) 170 (20%) 0.482 
Aspirin 1002 (83%) 286 (82%) 716 (83%) 0.672 
Clopidogrel 208 (17%) 64 (18%) 144 (17%) 0.490 
Warfarin 127 (11%) 24 (7%) 103 (12%) 0.009 
Statin 983 (81%) 284 (81%) 699 (81%) 0.879 
Nitrate 646 (53%) 177 (51%) 469 (54%) 0.243 
Antiarrhythmic 128 (11%) 41 (12%) 87 (10%) 0.393 
Insulin 197 (16%) 8 (2%) 189 (22%) <0.001 
Oral Diabetic agent 286 (24%) 38 (11%) 248 (29%) <0.001 
Coronary Anatomy     
Number of diseased vessels (75%)    0.268 
0 25 (2%) 8 (2%) 17 (2%)  
1 282 (23%) 83 (24%) 199 (23%)  
2 462 (38%) 145 (42%) 317 (37%)  
3 442 (37%) 113 (32%) 329 (38%)  
LM stenosis > 50% 32 (3%) 5 (1%) 27 (3%) 0.095 
Proximal LAD stenosis > 75% 826 (68%) 244 (70%) 582 (68%) 0.417 
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Abbreviations: BMI = body mass index; HR = heart rate; SBP = systolic blood pressure; CCS = 
Canadian Cardiovascular Society; NYHA = New York Heart Association; Hg = hemoglobin; sCr 
= serum creatinine; eGFR = estimated glomerular filtration rate; BUN = blood urea nitrogen; 
LVEF = left ventricular ejection fraction; ESVI = end-systolic volume index; 6-MWT = 6-
minute walk test; KCCQ = Kansas City Cardiomyopathy Questionnaire; PCI = percutaneous 
coronary intervention; CABG = coronary artery bypass grafting; MR = mitral regurgitation; 
PVD = peripheral vascular disease; MI = myocardial infarction; CVA = cerebral vascular 
accident; HL = hyperlipidemia; HTN = hypertension; DM = diabetes mellitus; afib/flutter = atrial 
fibrillation/flutter; CKD = chronic kidney disease; ACEI = angiotensin converting-enzyme 
inhibitor; ARB = angiotensin receptor blocker; MRA = mineralocorticoid receptor antagonist; 
LM = left main; LAD = left anterior descending.
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Table 2. Hazard ratio for categorized and continuous CCI for primary and secondary endpoints. 
 
 
Number of events  
(KM 10-year rate) Categorized CCI Continuous CCI 
Event 
Mild/ 
Moderate Severe 
Unadjusted  
HR (95% CI)  
for severe 
comorbidity p-value 
Adjusted  
HR (95% CI)  
for severe 
comorbidity* p-value 
Unadjusted  
HR (95% CI)  
for 1 point  
increase p-value 
Adjusted  
HR (95% CI)  
for 1 point 
increase* p-value 
All-cause mortality 161 (49.7%) 579 (69.3%) 1.73 (1.45, 2.06) <0.001 1.44 (1.19, 1.74) <0.001 1.17 (1.13, 1.22) <0.001 1.12 (1.06, 1.18) <0.001 
CV mortality 130 (42.2%) 408 (53.6%) 1.49 (1.23, 1.82) <0.001 1.35 (1.09, 1.68) 0.006 1.12 (1.07, 1.18) <0.001 1.11 (1.04, 1.18) <0.001 
All-cause mortality or CV 
hospitalization 
254 (79.1%) 731 (86.5%) 1.45 (1.25, 1.67) <0.001 1.22 (1.04, 1.43) 0.012 1.12 (1.09, 1.16) <0.001 1.07 (1.02, 1.12) 0.003 
 
* Adjusted for sex, race, region, blood pressure, heart rate, CCS angina class, NYHA class, atrial fibrillation/flutter, hyperlipidemia, 
hypertension, prior CABG, prior PCI, number of diseased vessels, left main stenosis, proximal LAD stenosis, LVEF, and LVESVI, 
moderate or severe mitral regurgitation, hemoglobin, sodium, eGFR, and randomized treatment 
 
Abbreviations: CV = cardiovascular; KM = Kaplan-Meier; CCI = Charlson Comorbidity Index; HR = hazard ratio; CI = confidence 
interval; CCS = Canadian Cardiovascular Society; NYHA = New York Heart Association; CABG = coronary artery bypass grafting; 
PCI = percutaneous coronary intervention; LAD = left anterior descending; LVEF = left ventricular ejection fraction; LVESVI = left 
ventricular systolic volume index; eGFR = estimated glomerular filtration rate.
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Figure 1A. Observed probability of 10-year all-cause mortality according to CCI. 
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Figure 1B. Predicted and observed 10-year mortality by CCI score. 
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Figure 2. Kaplan-Meier curves for treatment effect (i.e. MED vs. MED/CABG) by CCI category 
(i.e. mild/moderate vs. severe) for (A) all-cause mortality, (B) CV mortality, and (C) all-cause 
mortality or CV hospitalization. 
A 
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Figure 3. Spline curves for treatment effect (i.e. MED vs. MED/CABG) by CCI as a continuous variable for all-cause mortality, CV mortality, and all-cause mortality or CV hospitalization at 1, 5, and 10 years. 
   
   
   
Interaction: unadjusted p=0.115 Interaction: unadjusted p=0.275 Interaction: unadjusted p=0.021 
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Supplemental Table 1. Clinical variables and study definitions used to calculate modified CCI. 
 
Clinical Variables Points STICH 
Age  
 
    <40 0 
    41-50 1 
    51-60 2 
    61-70 3 
    >70 4 
Myocardial Infarction 1  
Heart Failure 1 All 
Peripheral Vascular Disease 1  
Cerebrovascular Disease 1  
Dementia 1 NA1,2 
Chronic Obstructive Pulmonary Disease 1  3 
Connective Tissue Disease 1 NA 
Peptic Ulcer Disease 1 NA 
Diabetes Mellitus 1-2 4 
Chronic Kidney Disease 2 5 
Hemiplegia 2 NA1 
Leukemia 2 
6,7 Malignant Lymphoma 2 
Solid Tumor 2-6 
Liver Disease 1-3 NA7 
AIDS 6 NA7 
 
1Patients were excluded if they were unable to provide informed consent or had medical 
conditions/circumstances likely to lead to poor treatment adherence 
2Depression was substituted for dementia when available 
3Active smoking was considered to be a chronic obstructive pulmonary disease equivalent 
4Patients with concomitant diabetes on oral hypoglycemic were assigned 1 point while insulin-
dependent diabetics were assigned 2 points 
5Defined as a serum creatinine >1.5 mg/dL 
6Cancer (excluding skin cancer) within the last 5 years 
7Patients were excluded if they had a non-cardiac illness with a life expectancy of less than 3 
years 
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Supplemental Figure 1. Kaplan-Meier curves for treatment effect (i.e. MED vs. MED/CABG) 
within CCI category (i.e. mild/moderate vs. severe) for (A) all-cause mortality, (B) CV mortality, 
and (C) all-cause mortality or CV hospitalization for the as-treated cohort. 
A 
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